SGMOQOTCBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
SANGAMO THERAPEUTICS, INC
Financials through Q1 FY2026, quarter ended Mar 31, 2026Last filing: 10-Q on May 14, 2026
$0.10−0.01 (-8.17%)
Close on Oct 19, 2026
- Market cap
- $39.43M
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2011 to 2025
Operating margin
-306.5%−196.9 pts over 5 years
Net margin
-310.8%−208.4 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | -31.6% | -29.2% | -19.7% | +0.0% |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | -43.6% | -26.0% | -2891.8% | |
| Return on assets | -38.2% | -15.4% | -152.4% | |
| Current ratio | 11.25 | 4.60 | 0.84 | |
| Capex to revenue | 3.8% | 12.4% | 0.3% | |
| Diluted shares | 71M | 134M | 280M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Sangamo Therapeutics generated $846.07M from operations and spent $64.97M on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$846.07M
Used
$64.97M
Capital expenditure$64.97M100%Dividends$00%Share buybacks$00%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-310.8%
×Asset turnover0.49×
×Equity multiplier18.98×
=Return on equity, FY2025-2891.8%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | -310.8% | 0.49× | 18.98× | -2891.8% |
| FY2024 | -169.4% | 0.43× | 2.53× | -185.4% |
| FY2023 | -146.3% | 0.48× | 1.93× | -136.5% |
| FY2022 | -172.8% | 0.17× | 1.92× | -57.4% |
| FY2021 | -161.1% | 0.13× | 1.90× | -40.8% |
| FY2020 | -102.4% | 0.15× | 1.69× | -26.0% |
| FY2019 | -92.9% | 0.17× | 1.54× | -23.8% |
| FY2018 | -80.9% | 0.19× | 1.58× | -24.7% |
| FY2017 | -149.2% | 0.16× | 1.37× | -33.7% |
| FY2016 | -369.6% | 0.10× | 1.14× | -43.6% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
2of 7 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero-$122.93M
- Cash generatingOperating cash flow above zero-$97.21M
- Return on assets improvedROA up on the prior year-59.2% → -121.0%
- Earnings backed by cashOperating cash flow above net income-$97.21M vs -$122.93M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose1.13 → 0.84
- No dilutionShare count did not rise202M → 280M
- Gross margin improvedGross margin up on the prior year– → –
- More efficientAsset turnover rose0.35 → 0.39